James Woodruff Emlen
Chief Tech/Sci/R&D Officer bij MenoGenix, Inc.
Profiel
James Woodruff Emlen was the founder of Taligen Therapeutics, Inc. founded in 2004 where he held the title of President from 2009 to 2010.
He is currently the Director & Chef Medical Officer at MenoGenix, Inc. Dr. Emlen's former positions include Vice President-Exploratory Medicine at Connetics Corp., Vice President-Scientific Affairs at InterMune, Inc., Faculty Member at the University of Washington, and Professor-Medicine & Immunology at The University of Colorado.
Dr. Emlen received his undergraduate degree from Stanford University and his doctorate from the University of California San Diego.
Actieve functies van James Woodruff Emlen
| Bedrijven | Functie | Begin |
|---|---|---|
MenoGenix, Inc.
 MenoGenix, Inc. BiotechnologyHealth Technology MenoGenix, Inc. operates as a biotechnology company. It focuses on development of drugs for menopause and the menopause diseases. The company was founded by Debra M. Duke and Jonathan Kaufman in 2010 and is headquartered in Aurora, CO. | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van James Woodruff Emlen
| Bedrijven | Functie | Einde |
|---|---|---|
Taligen Therapeutics, Inc.
 Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | Founder | 24-02-2012 |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
| INTERMUNE INC | Chief Tech/Sci/R&D Officer | - |
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | - |
| The University of Colorado | Corporate Officer/Principal | - |
Opleiding van James Woodruff Emlen
| Stanford University | Undergraduate Degree |
| University of California San Diego | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Connetics Corp.
Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Taligen Therapeutics, Inc.
Taligen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. | Health Technology |
MenoGenix, Inc.
MenoGenix, Inc. BiotechnologyHealth Technology MenoGenix, Inc. operates as a biotechnology company. It focuses on development of drugs for menopause and the menopause diseases. The company was founded by Debra M. Duke and Jonathan Kaufman in 2010 and is headquartered in Aurora, CO. | Health Technology |
